Previous 10 | Next 10 |
Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals PR Newswire SALT LAKE CITY , Feb. 2, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) diso...
2024-01-18 08:36:41 ET More on Lipocine Seeking Alpha’s Quant Rating on Lipocine Historical earnings data for Lipocine Financial information for Lipocine For further details see: Lipocine licenses Tlando testosterone therapy to Verity Pharma
Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada PR Newswire Lipocine to receive $11 million license fee Up to $259 million in development and commercial sales milestones Tiered royalties on net sales of ...
Lipocine to Present at Biotech Showcase 2024 PR Newswire Company Management Will Also Host Meetings at LifeSci Partners Corporate Access Event SALT LAKE CITY , Dec. 19, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on ...
2023-11-22 16:25:56 ET Lipocine ( NASDAQ: LPCN ) on Wednesday filed a prospectus for a mixed securities shelf offering of up to $150M. This prospectus is not an offer to sell these securities. SEC Filing For further details see: Lipocine files for $150M ...
Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023 PR Newswire Results demonstrate improvements in sarcopenia and other clinically meaningful outcomes Patients converting from placebo to LPCN 1148 in the ongoing open lab...
2023-11-08 08:43:25 ET Lipocine press release ( NASDAQ: LPCN ): Q3 GAAP EPS of -$1.27 misses by $0.67 . As of September 30, 2023, Lipocine had $23.8 million of unrestricted cash, cash equivalents and marketable investment securities compared to $32.5 million at Decembe...
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023 PR Newswire SALT LAKE CITY , Nov. 8, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by l...
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
Lipocine Inc. (LPCN) is expected to report $-0.57 for Q3 2023
News, Short Squeeze, Breakout and More Instantly...
Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154 PR Newswire Pivotal study design aligned with FDA on streamlined pathway to NDA submission goal in 2024 Topline results anticipated late in 2Q 2024 SALT LAKE CITY ...
2024-04-11 09:01:37 ET DENVER, Colo., Apr 11, 2024 ( 247marketnews.com )- Lipocine Inc. (NASDAQ: LPCN ) results from a Phase 2 clinical trial including LPCN 2401, an oral proprietary combination of anabolic androgen receptor agonist and α-tocopherol, an antioxidant, which sho...
Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity PR Newswire LPCN 2401 treatment resulted in statistically significant body composition improvement in men Increased lean mass (LM) by 4.4% and decreased fa...